Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 11/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28410234 | 0.99 | ALOX15 (0.49) | ALOX15CYP1A2GABRA2GABRB2ADORA2A | |
| SCHEMBL30688572 | 0.84 | CA12 (0.49) | CYP1A2MAPTKDM4E | |
| SCHEMBL13905447 | 0.84 | CA12 (0.49) | CYP1A2MAPTKDM4E | |
| SCHEMBL27613559 | 0.82 | CYP1A2 (0.54) | ALOX15CYP1A2GABRA2GABRB2ADORA2A | |
| SCHEMBL13905450 | 0.82 | KDM4E (0.53) | CYP1A2GABRA2GABRB2MAPTHSD17B10 | |
| SCHEMBL8830040 | 0.81 | CYP1A2 (0.56) | CYP1A2GABRA2GABRB2MAPTKDM4E | |
| SCHEMBL1503948 | 0.78 | PIK3CG (0.42) | GABRA2GABRB2HSD17B10 | |
| SCHEMBL6824675 | 0.77 | KDM4E (0.54) | ALOX15GABRA2GABRB2ADORA2AMAPT | |
| SCHEMBL21885348 | 0.77 | ALOX15 (0.50) | ALOX15CYP1A2GABRA2GABRB2MAPT | |
| SCHEMBL21885738 | 0.77 | ALOX15 (0.50) | ALOX15CYP1A2GABRA2GABRB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111630051-B | Olefin spiro compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-3704112-B1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3704114-B1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-29 | — | — | US | disclosed |
| US-11078198-B2 | Spirocyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3704114-A1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3704112-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| CN-111630051-A | Spirocyclic compounds of alkenes as farnesoid X receptor modulators | 百时美施贵宝公司 | 2020-09-04 | — | — | CN | disclosed |
| US-20190127362-A1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127362-A1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H4, FXR1, NR1H2 | ALOX15 418/4885CYP1A2 769/4885GABRA2 2003/4885 |
| US-11078198-B2 | Spirocyclic compounds as farnesoid X receptor modulators | NR1H4, FXR1, NR1H2 | ALOX15 418/4885CYP1A2 769/4885GABRA2 2003/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | ALOX15 838/4885CYP1A2 3257/4885GABRA2 1789/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | ALOX15 872/4885CYP1A2 2631/4885GABRA2 2235/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | ALOX15 872/4885CYP1A2 2631/4885GABRA2 2235/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | ALOX15 872/4885CYP1A2 2631/4885GABRA2 2235/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | ALOX15 872/4885CYP1A2 2631/4885GABRA2 2235/4885 |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | NR1H2, NR1H4, NR1H3 | ALOX15 347/4885CYP1A2 488/4885GABRA2 1472/4885 |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H2, NR1H4, NR1H3 | ALOX15 347/4885CYP1A2 488/4885GABRA2 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.